One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2021-145553
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 9 |
Affiliation: University Hospital Münster, Jena University Hospital, Klinikum Chemnitz, University Hospital Augsburg, Heidelberg University, University Hospital Heidelberg, Goethe University Frankfurt, University Hospital Frankfurt, Robert Bosch Hospital, University of Bonn, University Medical Center Freiburg, University of Freiburg, University Hospital Schleswig-Holstein, University of Lübeck, Heinrich Heine University Düsseldorf, Essen University Hospital, University of Erlangen-Nuremberg
Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
